Full Breakdown
Johnson & Johnson’s MedTech Segment Falters Amid Cardiovascular Headwinds and Orthopedic Spin-Off Plans
By Drooid · · How we work
Core Event – Q3 2026 MedTech Performance and Strategic Outlook
Johnson & Johnson’s medical-technology division posted third-quarter sales of $8.64 billion, a 2.5 % year-over-year increase that fell short of the $8.71 billion consensus estimate. Cardiovascular revenue reached $2.31 billion (up 4.3 %), while the Abiomed heart-pump business declined 2.3 % to $412 million after a disappointing U.K. clinical trial of the Impella device. Management said the slowdown is concentrated in sales outside the United States and in the Abiomed line, and confirmed that the orthopedics unit, DePuy Synthes, remains slated for a mid-2027 separation, with a spin-off now favored over a sale.
Background & Context
J&J acquired Abiomed in 2022 for $16.6 billion to expand its cardiovascular portfolio. The first quarter of 2026 saw double-digit growth in that segment, but subsequent quarters have trended downward as surgeons reduced procedure volumes following the Impella trial, which enrolled 300 patients with severe left-ventricular dysfunction. In late 2025 the company announced plans to separate its orthopedics business, marking the second major spinoff in its recent history.
Data & Statistics
| Metric | Q3 2026 | YoY Change |
|---|---|---|
| Total MedTech sales | $8.64 billion | +2.5 % |
| Cardiovascular sales | $2.31 billion | +4.3 % |
| Abiomed (Impella) sales | $412 million | –2.3 % |
| Surgical sales | –0.6 % (flat) | |
| Vision sales | $1.46 billion | +4.4 % |
| Orthopedics sales | $2.35 billion | +3.2 % |
| Innovative Medicine sales | $16.76 billion | +7.7 % |
| Tremfya (autoimmune) sales | $2.4 billion | +68 % |
| Darzalex (blood cancer) sales | $4.24 billion | +15 % |
| Overall revenue (all segments) | $25.4 billion | +5.9 % |
Analysts had projected MedTech growth of ~3 %, making the 2.5 % rise a shortfall.
Official Statements & Responses
Chief Financial Officer Joe Wolk said the division “needs to improve, quite frankly,” attributing weaker international sales to geopolitical tension in the Middle East, austerity measures in Europe, and pricing pressures in China. He added that the company is moving toward a straight spin of the orthopedics business as the preferred path to create long-term shareholder value.
Tim Schmid said the focus now is on education, expanding the clinical evidence base for Impella, and delivering stronger results in the fourth quarter.
Conflicting Reports & Gaps
Share-price reactions to the earnings release differ across sources: Bloomberg reported a 3.7 % decline in J&J’s stock during the morning trade, while Finchannel cited a more than 6 % drop on October 13, and BNN Bloomberg also described a “more than six per cent” fall. The discrepancy highlights a lack of consensus on the immediate market impact. No source provided detailed regional breakdowns of the MedTech slowdown beyond the broad “outside the U.S.” description.
What’s Next
J&J expects results from the PROTECT IV study of nearly 1,300 patients to be released next year, which could clarify the clinical profile of the Impella device. The company remains on track for a mid-2027 separation of DePuy Synthes, with the final decision on spin-off versus sale still pending. Additional details on the 2027 outlook and pipeline progress are slated for an enterprise-business review later in the year.